AstraZeneca COPD drug data lifts Citi sales outlook sharply
Citi analysts say AstraZeneca’s blowout clinical data for tozorakimab supports sales expectations sharply above current consensus estimates, according to a research note.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.